| NCT05208307 | Emory University|GlaxoSmithKline|National Cancer Institute (NCI) | Plasma Cell Myeloma | 2022-07-21 | PHASE2 |
| NCT07150104 | GlaxoSmithKline | Multiple Myeloma | 2022-08-31 | PHASE1|PHASE2 |
| NCT05065047 | M.D. Anderson Cancer Center | Multiple Myeloma | 2023-01-05 | PHASE1 |
| NCT07224672 | GlaxoSmithKline | Amyloidosis | 2026-03-20 | PHASE2 |
| NCT05714839 | GlaxoSmithKline | Multiple Myeloma | 2023-06-14 | PHASE1|PHASE2 |
| NCT06160609 | GlaxoSmithKline | Relapsed+Refractory Multiple Myeloma | 2019-10-07 | PHASE1|PHASE2 |
| NCT04484623 | GlaxoSmithKline | Multiple Myeloma | 2020-10-01 | PHASE3 |
| NCT06868667 | GlaxoSmithKline | Multiple Myeloma | 2021-07-28 | PHASE3 |
| NCT05556798 | Memorial Sloan Kettering Cancer Center | Multiple Myeloma | 2022-10-04 | PHASE1 |
| NCT03828292 | GlaxoSmithKline | Multiple Myeloma | 2019-03-14 | PHASE1 |
| NCT05064358 | GlaxoSmithKline | Multiple Myeloma | 2022-03-03 | PHASE2 |
| NCT05493618 | Hackensack Meridian Health|Merck Sharp & Dohme LLC | Multiple Myeloma, Refractory | 2022-12 | PHASE1|PHASE2 |
| NCT07285239 | PrECOG, LLC.|GlaxoSmithKline | Multiple Myeloma | 2026-05 | PHASE3 |
| NCT04896658 | University of Maryland, Baltimore | Relapsed+Refractory Multiple Myeloma | 2021-12-03 | PHASE1|PHASE2 |
| NCT03544281 | GlaxoSmithKline|IQVIA Pty Ltd | Multiple Myeloma | 2018-09-20 | PHASE1|PHASE2 |
| NCT07217184 | GlaxoSmithKline | Multiple Myeloma | 2021-07-29 | PHASE1|PHASE2 |
| NCT05055063 | M.D. Anderson Cancer Center | Myeloma | 2022-05-18 | PHASE1 |
| NCT06679101 | GlaxoSmithKline | Multiple Myeloma|Newly Diagnosed Multiple Myeloma | 2024-12-16 | PHASE3 |
| NCT04802356 | PETHEMA Foundation|GlaxoSmithKline | Multiple Myeloma | 2021-04-07 | PHASE2 |
| NCT07084896 | GlaxoSmithKline | Multiple Myeloma | 2020-06-08 | PHASE1|PHASE2 |
| NCT05393024 | Fondazione EMN Italy Onlus | Multiple Myeloma | 2022-07-22 | |
| NCT06956170 | GlaxoSmithKline | Multiple Myeloma | 2022-02-10 | PHASE3 |
| NCT06232044 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) | Recurrent Multiple Myeloma|Refractory Multiple Myeloma | 2025-04-23 | PHASE1|PHASE2 |
| NCT04680468 | University of Pennsylvania|GlaxoSmithKline | Myeloma | 2021-06-02 | PHASE2 |
| NCT05833737 | Medical University of Vienna | Multiple Myeloma|Corneal Diseases|Corneal Cyst | 2023-06-01 | |
| NCT03848845 | GlaxoSmithKline|Merck Sharp & Dohme LLC | Multiple Myeloma | 2019-03-14 | PHASE1|PHASE2 |
| NCT06413511 | GlaxoSmithKline | Autoimmune Diseases | 2024-06-03 | PHASE1 |
| NCT05847569 | Mayo Clinic | Recurrent Multiple Myeloma|Refractory Multiple Myeloma | 2024-01-04 | PHASE2 |
| NCT04822337 | Wake Forest University Health Sciences|Amgen|GlaxoSmithKline | Multiple Myeloma | 2021-05-19 | PHASE1|PHASE2 |
| NCT05789303 | University of Chicago|GlaxoSmithKline|Amgen | Multiple Myeloma|Relapse Multiple Myeloma | 2023-05-30 | PHASE2 |
| NCT02343042 | Karyopharm Therapeutics Inc|Bristol-Myers Squibb | Multiple Myeloma | 2015-10 | PHASE1|PHASE2 |
| NCT04549363 | GlaxoSmithKline | Multiple Myeloma | 2020-12-21 | PHASE3 |
| NCT07019545 | Hellenic Society of Hematology | Primary Immune Thrombocytopenia (ITP) | 2025-06-20 | PHASE2 |
| NCT04162210 | GlaxoSmithKline | Multiple Myeloma | 2020-04-02 | PHASE3 |
| NCT04398680 | GlaxoSmithKline | Multiple Myeloma | 2021-04-20 | PHASE1 |
| NCT05297240 | PETHEMA Foundation|GlaxoSmithKline | RELAPSED AND+OR REFRACTORY MULTIPLE MYELOMA | 2022-03-24 | |
| NCT03732703 | Multiple Myeloma Research Consortium|AbbVie|Celgene Corporation|Eli Lilly and Company|Genentech, Inc.|Janssen, LP|Takeda|GlaxoSmithKline|Karyopharm Therapeutics Inc | Relapsed Refractory Multiple Myeloma | 2019-04-01 | PHASE1|PHASE2 |
| NCT04808037 | Hellenic Society of Hematology|GlaxoSmithKline | Multiple Myeloma | 2021-02-22 | PHASE1|PHASE2 |
| NCT04676360 | Jacob Soumerai, MD|GlaxoSmithKline | Relapsed Plasmablastic Lymphoma|Refractory Plasmablastic Lymphoma|Anaplastic Lymphoma Kinase Positive Large B-Cell Lymphoma | 2021-07-01 | PHASE2 |
| NCT07227311 | GlaxoSmithKline | Multiple Myeloma | 2026-04-15 | PHASE2 |
| NCT03763370 | GlaxoSmithKline | Multiple Myeloma | | |
| NCT05280275 | Hellenic Society of Hematology|GlaxoSmithKline | Multiple Myeloma|Neoplasms|Neoplasms, Plasma Cell|Gammopathy, Monoclonal|Paraproteinemias|Blood Protein Disorders|Haematologic Disease|Corneal Disease | 2022-04-13 | PHASE1|PHASE2 |
| NCT05853965 | Universit?tsklinikum Hamburg-Eppendorf | Multiple Myeloma|Multiple Myeloma in Relapse | 2023-06-28 | PHASE1|PHASE2 |
| NCT04246047 | GlaxoSmithKline | Multiple Myeloma | 2020-05-07 | PHASE3 |
| NCT04398745 | GlaxoSmithKline | Multiple Myeloma | 2020-10-09 | PHASE1 |
| NCT03525678 | GlaxoSmithKline | Multiple Myeloma | 2018-06-18 | PHASE2 |
| NCT07150091 | GlaxoSmithKline | Multiple Myeloma | 2022-07-19 | PHASE1|PHASE2 |
| NCT04177823 | GlaxoSmithKline | Multiple Myeloma | 2019-12-09 | PHASE1 |
| NCT07217119 | GlaxoSmithKline | Multiple Myeloma | 2019-11-26 | PHASE1|PHASE2 |
| NCT05874193 | Cristiana Costa Chase, DO | Relapsed+Refractory Multiple Myeloma | 2026-05 | PHASE2 |
| NCT04876248 | Roswell Park Cancer Institute|GlaxoSmithKline | Plasma Cell Myeloma | 2024-08-19 | PHASE2 |
| NCT04091126 | GlaxoSmithKline | Multiple Myeloma | 2019-12-18 | PHASE1 |
| NCT05145816 | University of Texas Southwestern Medical Center|GlaxoSmithKline | AL Amyloidosis|Amyloidosis | 2024-02-15 | PHASE1|PHASE2 |
| NCT06868654 | GlaxoSmithKline | Multiple Myeloma | 2021-07-28 | PHASE3 |
| NCT05461209 | Janssen Research & Development, LLC | Relapsed+ Refractory Multiple Myeloma | 2022-10-20 | PHASE3 |
| NCT05060627 | PETHEMA Foundation|Adknoma Health Research | Relapsed Multiple Myeloma | 2021-12-20 | PHASE1|PHASE2 |
| NCT05573802 | Hellenic Society of Hematology|GlaxoSmithKline | Multiple Myeloma|Neoplasms|Neoplasm, Plasma Cell|Gammopathy, Monoclonal|Paraproteinemias|Blood Protein Disorders|Haematologic Disease|Corneal Disease | 2023-07-14 | PHASE1|PHASE2 |
| NCT05002816 | Yale University|GlaxoSmithKline | Multiple Myeloma | 2022-02-21 | PHASE1|PHASE2 |
| NCT05117008 | Medical College of Wisconsin | Refractory Multiple Myeloma|Relapse Multiple Myeloma | 2022-07-19 | PHASE2 |
| NCT06655818 | GlaxoSmithKline | Relapsed+Refractory Multiple Myeloma | 2021-03-09 | PHASE1|PHASE2 |
| NCT04617925 | Stichting European Myeloma Network|GlaxoSmithKline | AL Amyloidosis | 2021-02-26 | PHASE2 |
| NCT04643002 | Sanofi | Plasma Cell Myeloma Refractory | 2021-01-25 | PHASE1|PHASE2 |
| NCT05091372 | M.D. Anderson Cancer Center | Myeloma Multiple | 2022-12-01 | PHASE2 |
| NCT05581875 | Hellenic Society of Hematology|GlaxoSmithKline | Multiple Myeloma|Multiple Myeloma in Relapse|Neoplasms|Gammopathy, Monoclonal|Paraproteinemias|Blood Protein Disorders|Haematologic Disease|Corneal Disease|Neoplasms, Plasma Cell | 2022-10-20 | PHASE1|PHASE2 |